Streptococcus pneumoniae is an important pathogen responsible for serious invasive diseases, including meningitis and septicemia. The spread of multidrug-resistant (MDR) pneumococci has become a worldwide problem, making treatment more difficult (18). Indeed, in addition to resistance to penicillin, resistance to other antibiotics, including erythromycin, tetracycline, and chloramphenicol, has emerged and is spreading (10).
classes were classified as multidrug resistant. Erythromycin-nonsusceptible isolates were classified as having the macrolide (M) or macrolide-lincosamidestreptogramin B (MLS B ) phenotype. The M phenotype was scored when the isolate was nonsusceptible only to erythromycin. The MLS B phenotype was scored when the isolate was nonsusceptible to both erythromycin and clindamycin (20) . MICs of vancomycin and ciprofloxacin were only determined from 1 January 1999. An isolate with a MIC of ciprofloxacin of Ն4 g/ml was considered nonsusceptible according to the association with mutations in the genes encoding DNA topoisomerase IV and DNA gyrase A (36) .
Statistical analyses. SPSS software, version 13.0, was used for statistical analysis. The chi-square test or Fisher's exact test was used when appropriate. Two-sided P values of Ͻ0.05 were considered to be statistically significant. Correlations between antimicrobial nonsusceptibility rates were assessed using the Spearman correlation coefficient.
RESULTS
A total of 1,331 pneumococcus strains were isolated during an 11-year period in 24 hospitals and public health institutions across Portugal and were included in the study: 73.3% were isolated from blood, 20.4% from CSF, 4.5% from pleural fluid, and 1.9% from both blood and CSF ( Table 1 ). The age of the patient was known for 1,219 (91.6%) of the isolates. Ninetyseven (8.0%) isolates were from patients Ͻ1 year old, 156 (12.8%) were from patients 1 to 9 years old, 77 (6.3%) were from patients 10 to 14 years old, 557 (45.7%) were from patients 15 to 64 years old, and 332 (27.2%) were from patients Ն65 years of age. The ages of patients for the remaining 112 isolates were unknown.
The in vitro susceptibility data for 10 antimicrobial agents are presented in Table 2 . The proportion of penicillin-nonsusceptible isolates was 20.6% (18.0% with intermediate resistance [MIC of 0.1 to 1 g/ml] and 2.6% with high-level resistance [MIC of Ն2 g/ml]), and the MIC 90 was 0.5 g/ml (Table 2) . Isolates with intermediate penicillin resistance became more frequent: from 13.0% in the period 1994 to 1998 and 18.5% in 1999 to 2001 to 20% in 2002 to 2004 (P ϭ 0.047) (Table 3) . However, the percentage of isolates with high-level with high-level resistance (6.0%) were higher in children than in adults (15.8%; 1.0%, respectively) (P Ͻ 0.001) ( (Table 4) .
S. pneumoniae isolates that were nonsusceptible to either cefotaxime (P ϭ 0.001) or ceftriaxone (P ϭ 0.007) became rarer over time, from 5.2% and 3.7% (1994 to 1998), respectively, to 0. 7 (2002 to 2004) (Table 3) . S. pneumoniae isolates were classified for susceptibility to cephalosporins according to two sets of CLSI criteria: those in use before 2002 and those in use after 2002 (Table 5 ). Nonsusceptibility to celphalosporins appeared to be less frequent after 2002. According to the 2002 guidelines, isolates nonsusceptible to cefotaxime (P Ͻ 0.001) and ceftriaxone (P Ͻ 0.001) were more frequently recovered from CSF (6.4% and 5.7%, respectively) than from blood (1.3% and 1.0%, respectively). Using the CLSI guidelines in force before 2002, no such association was found for either cefotaxime (6.4% versus 5.5%; P ϭ 0.57) or ceftriaxone (5.7% versus 5.0%; P ϭ 0.66). Cefotaxime-nonsusceptible isolates were more prevalent in the 10-to 14-year-old age group (11.4%; P ϭ 0.005), whereas isolates that were nonsusceptible to ceftriaxone were most common in the 1-to 9-year-old age group (5.4%; P Ͻ 0.001) (Fig. 1) . The main serotype and serogroup among these isolates were serotype 14 (51.9% of isolates nonsusceptible to ceftriaxone and 56.3% of those nonsusceptible to cefotaxime) and serogroup 9 (25.9% for ceftriaxone and 25.0% for cefotaxime) ( Table 4) .
Among the 191 erythromycin-nonsusceptible (MIC, Ն0.5 g/ml) isolates recovered in this study (14.4% of all isolates; a Includes serogroups/types 4 (n ϭ 1), 8 (n ϭ 1), 10 (n ϭ 1), 11 (n ϭ 1); 22 (n ϭ 1), and 34 (n ϭ 1). . Erythromycin nonsusceptibility was associated with multidrug resistance (P ϭ 0.017) and with nonsusceptibility to penicillin plus erythromycin (P Ͻ 0.001) among children. In isolates from adults, erythromycin nonsusceptibility was also associated with tetracycline (P Ͻ 0.001), chloramphenicol (P ϭ 0.017), and ciprofloxacin (P ϭ 0.012) nonsusceptibility. Erythromycin-and clindamycin-nonsusceptible isolates were most frequent among the isolates from children 1 to 9 years of age (25.5% and 15.2% respectively), children Ͻ1 year of age (17.5% and 12.4%, respectively), and adults Ն65 years of age (16.6% and 10.4%, respectively) ( Fig. 1) . Many erythromycinnonsusceptible isolates were of serogroups 19 and 15, and serotype 33 emerged after the period 1999 to 2001. Overall, however, serotype frequencies did not change through time (P ϭ 0.068) ( Table 4) . During the period of the study, the frequencies of ciprofloxacin-and ofloxacin-nonsusceptible isolates reached 1.4% and 2.0%, respectively; the MIC 90 of both antibiotics was 2 g/ml (Table 2) . Isolates nonsusceptible to ciprofloxacin increased from 0.6% (1999 to 2001) to 1.8% (2003) and to 3.5% (2004) (P ϭ 0.04) ( Table 3 ). The percentage of pneumococci nonsusceptible to ofloxacin decreased from 3.3% (1994 to 1998) to 0.8% (1999 to 2001) and then increased to 2.3% (2002 to 2004) (P ϭ 0.04) ( Table 3 ). The proportion of isolates from children that were nonsusceptible to ciprofloxacin (1.3%) was not significantly different from that observed for isolates from adults (2.1%) (P ϭ 0.47) (Fig. 1) . Ciprofloxacin-nonsusceptible isolates were from serotypes 1, 6, 11, 22, and 33 and were mainly from serotype 14 (26.7%), which appeared only since the period 1999 to 2001 (Table 4) .
All isolates were susceptible to vancomycin, with a MIC 90 of 0.5 g/ml ( Table 2) .
The frequencies of multidrug-resistant pneumococci were 6.5% (1994 to 1998) and 6.2% (1999 to 2001) and then increased to 11.7% in 2002 to 2004 (P ϭ 0.002) ( Table 3 ). The proportions of multidrug-resistant isolates among blood (9.3%) and CSF (6.3%) isolates were similar (P ϭ 0.28) ( Table  1) . Isolates with multidrug resistance were most frequent in children of the 1-to 9-year-old age group and in adults Ն65 years old (Fig. 1) . Overall, the multidrug resistance of pneumococci isolated from children (13.1%) was higher than that from adults (6.7%) (P Ͻ 0.001). In children, the rate of multidrug-resistant isolates was mainly associated with macrolides (P ϭ 0.017), and in adults this rate was mainly associated with resistance to penicillin (P ϭ 0.001), tetracycline (P ϭ 0.005), macrolides (P Ͼ 0.001), chloramphenicol (P ϭ 0.037), and ciprofloxacin (P ϭ 0.03). Among multidrug-resistant isolates, Table 4 ). The 29 multidrug-resistant phenotypes observed during the 11 years of the study are shown in Table 6 . The predominant phenotype of multidrug resistance was nonsusceptibility to penicillin, tetracycline, erythromycin, and clindamycin. Strains with this phenotype were mostly serotypes 6, 14, 15, 19, and 24. The second most frequent phenotype was nonsusceptibility to penicillin, erythromycin, and trimethoprimsulfamethoxazole, and all isolates with this phenotype were serotype 14 or serotype 1. The multidrug-resistant phenotype involving nonsusceptibility to penicillin, tetracycline, and erythromycin (the third most frequent) was only found The first pneumococcal isolates nonsusceptible to penicillin to be described in Portugal were isolated in 1989 (4.6%) as part of a collection of strains from invasive and noninvasive diseases (32) . Such strains became more widespread over the years, until they made up 9% (1992 to 1994) of isolates collected from (9) . It was, however, similar to those of several eastern European countries (9) and higher than those in Italy (12.1% in 1999 to 2000) (27) , Belgium (17.7% in 2000) (12), Luxembourg (11.2% in 2004) , and the majority of the northern European countries (9) . Differences in rates of pneumococcal penicillin resistance between countries have been shown to be associated with levels of antimicrobial consumption (3, 5, 13) .
We found that penicillin nonsusceptibility was associated with macrolides (P ϭ 0.002), trimethoprim-sulfamethoxazole (P ϭ 0.017), and multidrug resistance (P ϭ 0.001). Similar associations have been reported elsewhere in the world (18, 22, 33) . Previous studies in Portugal gave similar findings, except for macrolides (6, 32) ; however, the resistance to macrolides was very low when these studies were conducted.
Despite nonsusceptibility being relatively prevalent in Portugal, the frequency of isolates with high-level resistance declined consistently, to 0.9% in 2001 to 2004. Work in animal models (1, 37) and humans (25, 41) suggests that high-level penicillin resistance is associated with decreased virulence of pneumococci. Several studies reported that nonmeningeal pneumococcal infections caused by isolates with a penicillin MIC of Յ2 g/ml can be treated successfully with penicillin (31, 43) . However, in severely ill patients with pneumococcal bacteremia, combination antibiotic therapy reduces mortality (2) . Several studies have suggested that initial monotherapy with ␤-lactams for severe pneumococcal bacteremia may be suboptimal, and the use of combined therapy involving a macrolide or quinolone may improve the outcome of the disease (2, 39) . Empirical combination antibiotherapy avoids discordant therapy in the context of multidrug-resistant isolates but also causes a selection pressure on those isolates.
Using the 2004 CLSI guidelines (29), we found that ceftriaxone-and cefotaxime-nonsusceptible isolates became less prevalent over time and made up Յ1% of the isolates in 2004. Nevertheless, according to previous CLSI guidelines (28), the frequency of isolates nonsusceptible to cephalosporin was sta- These apparent differences are due to the changes in the CLSI susceptibility interpretation according to the source of isolation. Indeed, the number of isolates recovered from blood or CSF in the study influences the total frequency of nonsusceptible isolates. This fact can cause misleading interpretations of the frequency trends of cephalosporin-nonsusceptible isolates. Earlier studies indicated that cephalosporin-nonsusceptible isolates started to increase after 1993 (6), and our study suggests that their prevalence started to decline after the introduction of the pneumococcal conjugate vaccine in 2001. These findings support the recommendations for the use of cephalosporins, alone or combination with vancomycin, as initial empirical therapy for treatment of bacterial meningitis (16, 42) . In Portugal, the antibiotics most used for meningitis have been ceftriaxone (87%) and cefotaxime (10%) (4) .
The rates of resistance to macrolides have increased worldwide (19) , consistent with our findings in Portugal. This is mainly due to the widespread use of macrolides, mostly azithromycin (8, 19) . In Portugal, the predominant macrolide phenotype was MLS B , as shown in this study and among isolates recovered from respiratory tract infections (24) . The majority of southern European countries also have a high prevalence of the MLS B phenotype (34) . In contrast, the M phenotype is predominant in the United States (23) .
The rate of isolates nonsusceptible only to erythromycin (3.7% in 1994 to 1998 to 9.1% in 2002 to 2004) showed the same increasing trend as the rate of isolates with coresistance to penicillin and erythromycin (3.3% in 1994 to 1998 to 9.1% in 2002 to 2004). The increasing use of macrolides could be causing the increase of penicillin and multidrug resistances, due to the coresistance to macrolides. Fatal cases due to macrolide resistance have been described following azithromycin monotherapy (40) . The new ketolide, telithromycin, is a potential alternative to the currently used macrolides. However, isolates resistant to telithromycin have already been reported all over the world (15, 35) . It seems that telithromycin may be of limited therapeutic value in the long term due to the associated resistance mechanism (14) .
We found a significant frequency of isolates resistant to tetracycline and chloramphenicol. These antibiotics are not commonly used in Portugal (13) . The high prevalence of such strains can be explained by coresistance, mainly between tetracycline and macrolides. This coresistance is commonly associated with the presence of several transposons which carry the genetic determinants encoding resistance to both antibiotics (21, 26) .
Nonsusceptibility to ciprofloxacin increased in recent years from 0.5% in 2002 to 3.5% in 2004. This was associated with multidrug resistance, mainly among adults. In other studies, an association between ciprofloxacin resistance and individuals Ն65 years old has been observed (17, 38) . This antibiotic is mostly used in elderly individuals.
Multidrug resistance increased in the last years of our study: from 7.9% in 2002 to 15 .6% in 2004. In children, this mainly involved resistance to macrolides; in adults, it was mostly nonsusceptibility to penicillin, macrolides, and ciprofloxacin. The increasing resistance may be associated with the increased use of these antibiotics in recent years (8, 13) .
In view of the antibiotic resistance patterns among pneumococci in Portugal, penicillin should be used to treat uncomplicated nonmeningeal pneumococcal infections. The use of cephalosporins to treat meningeal pneumococcal infections and their use combined with a macrolide or quinolone to treat several nonmeningeal pneumococcal infections seem also to be reasonable choices.
